Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH. Co-formulation of the peptide agonist with an oral absorption enhancer prevents deactivation in the digestive tract and allows for daily oral administration. Preclinical studies have demonstrated good safety and efficacy profiles for XW004. The single-center, double-blind, placebo-controlled, and multiple ascending dose (MAD) study will evaluate XW004 at doses of up to 30 mg daily in approximately 56 healthy volunteers. Participants in the trial, which is being conducted in Australia, will be treated with the study drug once daily for 15 days with a 21-day treatment-free follow-up period. The objective of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW004. "As a once-daily oral GLP-1 tablet, XW004 has the potential to offer a more convenient treatment option for patients with metabolic disease and improve the overall compliance in broader patient populations. It is also amenable to developing oral combination treatments with other drugs to further enhance treatment outcomes," said Dr. Hai Pan, founder and CEO of Sciwind. "Initiation of this Phase 1 MAD study is an important first step towards developing XW004 as a safe and effective treatment for patients living with metabolic disease." About Sciwind Biosciences Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates. Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!